Indications for Use

• Treatment of HIV-1 infection in adults and adolescents as part of combination antiretroviral therapy.
• Pre-Exposure Prophylaxis (PrEP): Reducing the risk of HIV infection in individuals at high risk of exposure.

Contraindications

• Hypersensitivity to tenofovir, emtricitabine, or any excipients.
• Severe renal impairment (creatinine clearance <30 mL/min).
• Concurrent use with other medications containing tenofovir or emtricitabine.

Adverse Effects

Common:

• Headache, nausea, diarrhea, dizziness, rash, fatigue.

Rare:

• Lactic acidosis, hepatomegaly, renal impairment, osteomalacia.

Very rare:

• Pancreatitis, rhabdomyolysis, allergic reactions.

Recommendations for Use

Administration:

• Take tablets orally with sufficient water, preferably with food.

Precautions:

• Conduct an HIV test before initiating therapy.
• Regularly monitor renal function and viral load during treatment.
• Avoid concurrent use with nephrotoxic drugs.

Special Instructions:

• If symptoms of lactic acidosis occur (e.g., weakness, shortness of breath, abdominal pain), discontinue the medication immediately and seek medical attention.
• This medication does not completely prevent HIV transmission. For maximum protection, combine medication with barrier contraception methods.

Before starting treatment or prophylaxis, consult a healthcare provider and review the full prescribing information.

Oral coated tablets for oral use
- To be taken once a day, regardless of food intake
- Used as part of combination HIV therapy or as a single component of PrEP.